← Back to patent-cliff list
NTX-001
Tier C — Watch / tradeNTX-001
Neuraptive Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Peripheral nerve injury, 面瘫
Regional status
US
Phase III
2025-02-10
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NTX-001?
Approved indications include: Peripheral nerve injury, 面瘫.
When does the NTX-001 patent expire?
No public expiry year is available for NTX-001 yet; this page updates once verified.
How do I get a quote for NTX-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01